Qube Research & Technologies (QRT)
KROS icon

Qube Research & Technologies (QRT)’s Keros Therapeutics KROS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8M Sell
724,926
-58,992
-8% -$911K 0.01% 1411
2025
Q4 		$16M Buy
783,918
+480,796
+159% +$8.44M 0.02% 1038
2025
Q3 		$4.8M Buy
303,122
+264,445
+684% +$3.91M 0.01% 1776
2025
Q2 		$516K Sell
38,677
-234,665
-86% -$3.17M ﹤0.01% 2683
2025
Q1 		$2.79M Buy
+273,342
New +$3.17M ﹤0.01% 1824
2024
Q4 		– Sell
-27,941
Closed -$1.62M – 3667
2024
Q3 		$1.62M Sell
27,941
-3,294
-11% -$163K ﹤0.01% 1843
2024
Q2 		$1.43M Buy
31,235
+28,973
+1,281% +$1.56M ﹤0.01% 1755
2024
Q1 		$150K Sell
2,262
-32,280
-93% -$1.91M ﹤0.01% 3155
2023
Q4 		$1.37M Buy
34,542
+25,584
+286% +$802K ﹤0.01% 1735
2023
Q3 		$286K Sell
8,958
-17,880
-67% -$668K ﹤0.01% 2268
2023
Q2 		$1.08M Sell
26,838
-10,773
-29% -$472K ﹤0.01% 1272
2023
Q1 		$1.61M Buy
37,611
+24,631
+190% +$1.24M 0.01% 1106
2022
Q4 		$623K Sell
12,980
-9,036
-41% -$422K ﹤0.01% 1394
2022
Q3 		$828K Sell
22,016
-32,015
-59% -$1.11M ﹤0.01% 1266
2022
Q2 		$1.49M Buy
+54,031
New +$2.37M 0.01% 937

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Qube Research & Technologies (QRT)'s KROS Position: Q1 2026 in Review

Qube Research & Technologies (QRT) reduced its Keros Therapeutics (KROS) stake by 7.5% in Q1 2026, selling an estimated $911K and leaving 724,926 shares worth $8M. The position accounts for 0.01% of the portfolio, ranked #1411.

Qube Research & Technologies (QRT) first reported a position in KROS in Q2 2022 and has held it in 15 quarters since. The position peaked at $16M in Q4 2025. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • Qube Research & Technologies (QRT) held 724,926 shares of Keros Therapeutics worth $8M as of Q1 2026.
  • Qube Research & Technologies (QRT) sold 58,992 Keros Therapeutics shares in Q1 2026, an estimated $911K.
  • Keros Therapeutics made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #1411 holding.
  • Qube Research & Technologies (QRT) first reported a position in Keros Therapeutics in Q2 2022 and has held it in 15 quarters since.
  • Qube Research & Technologies (QRT)'s Keros Therapeutics position peaked at $16M in Q4 2025.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.